Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

NCT04632927 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

BIOLOGICAL: Secukinumab
BIOLOGICAL: Ustekinumab

Sponsor

Novartis Pharmaceuticals